English | 繁體

Search in the results

UM

Browse/Search Results:  1-7 of 7 Help

Selected(0)Clear Items/Page:    Sort:
Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing Journal article
Zhou, Yan, Guo, Yizhen, Ran, Maoxin, Shan, Wenying, Granchi, Carlotta, Giovannetti, Elisa, Minutolo, Filippo, Peters, Godefridus J., Tam, Kin Yip. Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing[J]. Cancer Letters, 2023, 577, 216425.
Authors:  Zhou, Yan;  Guo, Yizhen;  Ran, Maoxin;  Shan, Wenying;  Granchi, Carlotta; et al.
Favorite | TC[WOS]:9 TC[Scopus]:7  IF:9.1/8.3 | Submit date：2023/12/04
Anticancer  Combination Treatment  Non-small Cell Lung Cancer  Warburg Effect  
Epigallocatechin gallate circumvents drug induced resistance in non-small cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axis Journal article
Zhou, Yan, Huang, Shiqi, Guo, Yizhen, Ran, Maxoin, Shan, Wenying, Wen-Hau Chen, Tam, Kin Yip. Epigallocatechin gallate circumvents drug induced resistance in non-small cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axis[J]. Phytotheraphy Research, 2023, 37(12), 5837-5853.
Authors:  Zhou, Yan;  Huang, Shiqi;  Guo, Yizhen;  Ran, Maxoin;  Shan, Wenying; et al.
Favorite | TC[WOS]:6 TC[Scopus]:7  IF:6.1/7.0 | Submit date：2023/08/22
Acquired Drug Resistance  Combination Therapy  Egcg  Egfr-tkis  Nsclc  Synergetic Effect  
Repurposing the Hedgehog pathway inhibitor, BMS-833923, as a phosphatidylglycerol-selective membrane-disruptive colistin adjuvant against ESKAPE pathogens Journal article
Zhang,Nian, Shan,Wenying, Gao,Liangliang, Kou,Si Hoi, Lu,Chang, Yang,Huilin, Peng,Bo, Tam,Kin Yip, Lee,Leo Tsz On, Zheng,Jun. Repurposing the Hedgehog pathway inhibitor, BMS-833923, as a phosphatidylglycerol-selective membrane-disruptive colistin adjuvant against ESKAPE pathogens[J]. International Journal of Antimicrobial Agents, 2023, 62(3), 106888.
Authors:  Zhang,Nian;  Shan,Wenying;  Gao,Liangliang;  Kou,Si Hoi;  Lu,Chang; et al.
Favorite | TC[WOS]:4 TC[Scopus]:4  IF:4.9/5.6 | Submit date：2023/08/03
Antibiotic Resistance  Colistin Adjuvant  Drug Repurposing  Eskape  Membrane-disruptive Drug  
Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer models Journal article
Guo, Yizhen, Zhou, Yan, Wu, Puhua, Ran, Maoxin, Xu, Ngai, Shan, Wenying, Sha, Ou, Tam, Kin Yip. Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer models[J]. Chemico-Biological Interactions, 2023, 378, 110467.
Authors:  Guo, Yizhen;  Zhou, Yan;  Wu, Puhua;  Ran, Maoxin;  Xu, Ngai; et al.
Favorite | TC[WOS]:5 TC[Scopus]:5  IF:4.7/4.6 | Submit date：2023/07/19
Anticancer Effect  Dichloroacetophenone  Metabolic Alteration  Nsclc  Pdk  
GcForest-based compound-protein interaction prediction model and its application in discovering small-molecule drugs targeting CD47 Journal article
Shan, Wenying, Chen, Lvqi, Xu, Hao, Zhong, Qinghao, Xu, Yinqiu, Yao, Hequan, Lin, Kejiang, Li, Xuanyi. GcForest-based compound-protein interaction prediction model and its application in discovering small-molecule drugs targeting CD47[J]. Frontiers in Chemistry, 2023, 11.
Authors:  Shan, Wenying;  Chen, Lvqi;  Xu, Hao;  Zhong, Qinghao;  Xu, Yinqiu; et al.
Favorite | TC[WOS]:3 TC[Scopus]:2  IF:3.8/4.8 | Submit date：2024/02/22
Artificial Intelligence  Compound-protein Interaction Prediction  Gcforest  Small-molecule Cd47 Inhibitors  Word2vec  
The development of small-molecule inhibitors targeting hexokinase 2 Review article
2022
Authors:  Shan, Wenying;  Zhou, Yan;  Tam, Kin Yip
Favorite | TC[WOS]:22 TC[Scopus]:20  IF:6.5/7.3 | Submit date：2022/08/05
Cancer Metabolism  Hexokinase 2  Drug–target Binding  Selective Inhibition  Structure-based Molecular Design  
Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors Journal article
Shuang Zhang, Shan Yu, Wenying Hou, Xiaoying Li, Chunping Ning, Yingnan Wu, Feng Zhang, Yu Fei Jiao, Leo Tsz On Lee, Litao Sun. Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors[J]. JOURNAL OF OVARIAN RESEARCH, 2019, 12(1).
Authors:  Shuang Zhang;  Shan Yu;  Wenying Hou;  Xiaoying Li;  Chunping Ning; et al.
Favorite | TC[WOS]:14 TC[Scopus]:16  IF:3.8/4.2 | Submit date：2020/05/15
Borderline Ovarian Tumor  Preoperative Evaluation  Risk Of Malignancy Index  Differential Diagnosis  Benign Ovarian Tumor